- Study to look at DehydraTECHTM CBD’s means to regulate blood strain
- First of three human medical research hoped to validate Lexaria’s patented expertise for hypertension reduction
KELOWNA, BC / ACCESSWIRE / April 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a world innovator in drug supply platforms, publicizes that its human medical hypertension research HYPER-H21-1 is formally underway. Lexaria’s patented DehydraTECH CBD formulation might be examined to evaluate its means to regulate blood strain and assess affect on irritation.
“We are very pleased that dosing of human volunteers as part of Lexaria’s hypertension study has begun,” stated Lexaria CEO Mr. Chris Bunka. “Dosing is expected to be completed, on schedule, within several weeks, and we may be in a position to report preliminary data in July or thereabouts. Despite challenges in launching a human clinical study during a global pandemic, Lexaria’s Europe-based research partners have done an excellent job of balancing the need for scientific validation for a potential new hypertension treatment, with the required safety protocols currently in place.”
HYPER-H21-1 is a randomized, double-blinded, managed human medical research anticipated to contain 24 human volunteers with signs of both pre-hypertension, or delicate hypertension. A single 300mg dose of a sophisticated DehydraTECHTM 2.0 CBD formulation might be evaluated relative to a concentration-matched management with out Lexaria’s DehydraTECH enhancements.
Time collection blood strain and coronary heart fee analyses are the first goals of this research. Secondary goals embrace pace and fee of absorption of the CBD and its essential metabolites (pharmacokinetics or “PK” assessments), in addition to analysis of inflammatory markers related to heart problems and gold-standard biomarkers of nitric oxide. This latter measure gives mechanistic perception into the anticipated discount in blood strain through vasodilation.
These inflammatory marker assessments may additionally be relevant to Lexaria’s analysis initiatives within the antiviral therapeutics area whereby efficient anti-inflammatory therapies are additionally helpful in treating ailments like COVID-19 or different frequent pro-inflammatory circumstances.
Since a big array of information factors might be generated and analyzed, remaining reporting on this research is prone to be reported in early September.
There are 5 research in Lexaria’s 2021 hypertension program that are anticipated to generate information required to additional help the validity of utilizing DehydraTECH-processed CBD as a possible hypertension remedy throughout varied functions. Lexaria has obtained 18 granted patents internationally, together with issuances within the European Union and Australia particularly to make use of DehydraTECH-processed CBD to deal with coronary heart illness.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug supply expertise, DehydraTECH™, improves the way in which lively pharmaceutical substances (APIs) enter the bloodstream by selling more healthy oral ingestion strategies and rising the effectiveness of fat-soluble lively molecules, thereby decreasing general dosing. The Company’s expertise might be utilized to many alternative ingestible product codecs, together with meals, drinks, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the power to extend bio-absorption by as much as 5-10x, scale back time of onset from 1 – 2 hours to minutes, and masks undesirable tastes; and is deliberate to be additional evaluated for orally administered bioactive molecules, together with anti-virals, cannabinoids, nutritional vitamins, non-steroidal anti-inflammatory medication (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to a number of corporations together with a world-leading tobacco producer for the event of smokeless, oral-based nicotine merchandise and to be used in industries that produce cannabinoid drinks, edibles, and oral merchandise. Lexaria operates a licensed in-house analysis laboratory and holds a sturdy mental property portfolio with 18 patents granted and roughly 60 patents pending worldwide. For extra info, please go to www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press launch contains forward-looking statements. Statements as such time period is outlined beneath relevant securities legal guidelines. These statements could also be recognized by phrases equivalent to “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and different related expressions. Such forward-looking statements on this press launch embrace, however aren’t restricted to, statements by the corporate relating the Company’s means to hold out analysis initiatives, obtain regulatory approvals or grants or expertise optimistic results or outcomes from any analysis or research. Such forward-looking statements are estimates reflecting the Company’s greatest judgment based mostly upon present info and contain quite a lot of dangers and uncertainties, and there might be no assurance that the Company will truly obtain the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you shouldn’t place undue reliance on these forward-looking statements. Factors which might trigger precise outcomes to vary materially from these estimated by the Company embrace, however aren’t restricted to, authorities regulation and regulatory approvals, managing and sustaining development, the impact of adversarial publicity, litigation, competitors, scientific discovery, the patent software and approval course of, potential adversarial results arising from the testing or use of merchandise using the DehydraTECH expertise, the Company’s means to take care of current collaborations and notice the advantages thereof, delays or cancellations of deliberate R&D that would happen associated to pandemics or for different causes, and different components which can be recognized every so often within the Company’s public bulletins and periodic filings with the US Securities and Exchange Commission on EDGAR. There is not any assurance that any of Lexaria’s postulated makes use of, advantages, or benefits for the patented and patent-pending expertise will the truth is be realized in any method or in any half. No assertion herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated merchandise aren’t meant to diagnose, deal with, treatment or forestall any illness. Any forward-looking statements contained on this launch communicate solely as of the date hereof, and the Company expressly disclaims any obligation to replace any forward-looking statements contained herein, whether or not on account of any new info, future occasions, modified circumstances or in any other case, besides as in any other case required by legislation.
The CSE has not reviewed and doesn’t settle for accountability for the adequacy or accuracy of this launch.
SOURCE: Lexaria Bioscience Corp.
View supply model on accesswire.com: